Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of SEK 648.27 million. The enterprise value is 671.85 million.
Important Dates
The last earnings date was Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncopeptides AB has 395.29 million shares outstanding. The number of shares has increased by 49.53% in one year.
| Current Share Class | 381.36M |
| Shares Outstanding | 395.29M |
| Shares Change (YoY) | +49.53% |
| Shares Change (QoQ) | -6.24% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 9.39% |
| Float | 379.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.26 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.75
| Current Ratio | 3.75 |
| Quick Ratio | 3.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -199.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -101.27% |
| Return on Invested Capital (ROIC) | -82.90% |
| Return on Capital Employed (ROCE) | -140.34% |
| Weighted Average Cost of Capital (WACC) | 1.33% |
| Revenue Per Employee | 1.46M |
| Profits Per Employee | -2.76M |
| Employee Count | 71 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 0.33 |
Taxes
In the past 12 months, Oncopeptides AB has paid 1.85 million in taxes.
| Income Tax | 1.85M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.97% in the last 52 weeks. The beta is -0.50, so Oncopeptides AB's price volatility has been lower than the market average.
| Beta (5Y) | -0.50 |
| 52-Week Price Change | -67.97% |
| 50-Day Moving Average | 1.92 |
| 200-Day Moving Average | 1.73 |
| Relative Strength Index (RSI) | 40.16 |
| Average Volume (20 Days) | 3,176,673 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of SEK 103.50 million and -196.04 million in losses. Loss per share was -0.61.
| Revenue | 103.50M |
| Gross Profit | 99.90M |
| Operating Income | -185.19M |
| Pretax Income | -194.20M |
| Net Income | -196.04M |
| EBITDA | -183.05M |
| EBIT | -185.19M |
| Loss Per Share | -0.61 |
Full Income Statement Balance Sheet
The company has 116.84 million in cash and 140.42 million in debt, with a net cash position of -23.58 million or -0.06 per share.
| Cash & Cash Equivalents | 116.84M |
| Total Debt | 140.42M |
| Net Cash | -23.58M |
| Net Cash Per Share | -0.06 |
| Equity (Book Value) | -16.50M |
| Book Value Per Share | -0.04 |
| Working Capital | 120.78M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -192.57M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.13M |
| Net Borrowing | -8.16M |
| Free Cash Flow | -192.57M |
| FCF Per Share | -0.49 |
Full Cash Flow Statement Margins
Gross margin is 96.52%, with operating and profit margins of -178.92% and -189.41%.
| Gross Margin | 96.52% |
| Operating Margin | -178.92% |
| Pretax Margin | -187.63% |
| Profit Margin | -189.41% |
| EBITDA Margin | -176.86% |
| EBIT Margin | -178.92% |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -49.53% |
| Shareholder Yield | -49.53% |
| Earnings Yield | -37.06% |
| FCF Yield | -29.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for Oncopeptides AB is 2.70, which is 64.63% higher than the current price. The consensus rating is "Hold".
| Price Target | 2.70 |
| Price Target Difference | 64.63% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 66.45% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |